dc.contributor.author | Ordóñez-Mena, José Manuel | |
dc.contributor.author | Schöttker, Ben | |
dc.contributor.author | Mons, Ute | |
dc.contributor.author | Jenab, Mazda | |
dc.contributor.author | Freisling, Heinz | |
dc.contributor.author | Bueno-De-Mesquita, Hendrik Bastiaan | |
dc.contributor.author | O'Doherty, Mark G. | |
dc.contributor.author | Scott, Angela | |
dc.contributor.author | Kee, Frank | |
dc.contributor.author | Stricker, Bruno H. | |
dc.contributor.author | Hofman, Albert | |
dc.contributor.author | de Keyser, Catherine E. | |
dc.contributor.author | Ruiter, Rikje | |
dc.contributor.author | Söderberg, Stefan | |
dc.contributor.author | Jousilahti, Pekka | |
dc.contributor.author | Kuulasmaa, Kari | |
dc.contributor.author | Freedman, Neal D. | |
dc.contributor.author | Wilsgaard, Tom | |
dc.contributor.author | de Groot, Lisette C.P.G.M. | |
dc.contributor.author | Kampman, Ellen | |
dc.contributor.author | Håkansson, Niclas | |
dc.contributor.author | Orsini, Nicola | |
dc.contributor.author | Wolk, Alicja | |
dc.contributor.author | Nilsson, Lena Maria | |
dc.contributor.author | Tjønneland, Anne | |
dc.contributor.author | Pająk, Andrzej | |
dc.contributor.author | Malyutina, Sofia | |
dc.contributor.author | Kúbinová, Růžena | |
dc.contributor.author | Tamosiunas, Abdonas | |
dc.contributor.author | Bobak, Martin | |
dc.contributor.author | Katsoulis, Michail | |
dc.contributor.author | Orfanos, Philippos | |
dc.contributor.author | Boffetta, Paolo | |
dc.contributor.author | Trichopoulou, Antonia | |
dc.contributor.author | Brenner, Hermann | |
dc.date.accessioned | 2017-02-27T12:23:43Z | |
dc.date.available | 2017-02-27T12:23:43Z | |
dc.date.issued | 2016-04-05 | |
dc.description.abstract | Background:<br>
Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality.<br>
Methods:<br>
This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs.<br>
Results:<br>
Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking.<br>
Conclusions:<br>
This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation.<br>
Keywords:<br>
Smoking Cancer Incidence Mortality Cohort Meta-analysis | en_US |
dc.description.sponsorship | This work was supported by the FP7 framework program of DG-RESEARCH in the European Commission (Grant no. 242244). The CHANCES project (www.chancesfp7.eu) is coordinated by the Hellenic Health Foundation, Greece. The Cohort of Swedish Men (COSM) and the Swedish Mammography Cohort (SMC) were supported by research grants from the Swedish Research Council and the Swedish Cancer Foundation. The ESTHER study was funded by the Baden-Württemberg state Ministry of Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of Education and Research (Berlin, Germany), and the Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany). The EPIC Greece study was funded by the Hellenic Health Foundation. The EPIC Netherlands study was funded by European Commission (DG SANCO), Dutch Ministry of Public Health, Welfare and Sports (VWS), The National Institute for Public Health and the Environment (RIVM), the Netherlands Cancer Registry (NKR), the Netherlands Organization for Health Research and Development (ZONMW), the World Cancer Research Fund (WCRF) and Statistics Netherlands. The EPIC Spain study was supported by Health Research Fund (FIS) of the Spanish Ministry of Health RTICC ‘Red Temática de Investigación Cooperativa en Cáncer (Grant numbers: Rd06/0020/0091 and Rd12/0036/0018), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (project 6236) and Navarra, Instituto de Salud Carlos III, Redes de Investigación Cooperativa (RD06/0020). The EPIC Sweden study was funded by the Swedish Cancer Society, the Swedish Scientific Council and the Regional Government of Skåne. The EPIC Denmark study was funded by the Danish Cancer Society. The HAPIEE study was funded by the Welcome Trust (064947 and 081081), the US National Institute on Ageing (R01 AG23522), and a grant from Mac Arthur Foundation. MORGAM PRIME was supported by grants from the Institut National de la Santé et de la Recherche Médicale (INSERM), Merck, Sharp & Dohme-Chibret Laboratory and the Department of Health and Social Services and Personal Safety for Northern Ireland. In addition to the FP7 funding for CHANCES, the MORGAM project received funding from the European Union FP7 projects ENGAGE (HEALTH-F4-2007-201413) and BiomarCaRE (278913). This supported central coordination, workshops and part of the activities of the MORGAM Data Center at THL in Helsinki, Finland. MORGAM Participating Centers are funded by regional and national governments, research councils, charities, and other local sources. The National Institutes of Health (NIH)-AARP cohort was funded by the Intramural Program of the National Cancer Institute. The Rotterdam Study (RS) is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development; the Research Institute for Diseases in the Elderly; the Netherlands Genomics Initiative; the Ministry of Education, Culture, and Science; the Ministry of Health, Welfare, and Sports; the European Commission; and the Municipality of Rotterdam. The SENECA study was funded as a Concerted Action within the EURONUT programme of the EU. The TROMSØ Study was funded by the Norwegian Research Council and performed by the University of Tromsø in cooperation with the National Health Screening Service. The Västerbotten Intervention Program (VIP) was supported by grants from the Västerbotten County Council, the Swedish Council for Working Life and Social Research, and the Swedish Research Council. The study’s funders had no influence on the design of the study, analysis and interpretation of the data, writing, review, approval or submission of the manuscript. | en_US |
dc.description | Source: <a href=http://dx.doi.org/10.1186/s12916-016-0607-5>doi: 10.1186/s12916-016-0607-5</a> | en_US |
dc.identifier.citation | Ordóñez-Mena JM, Schöttker B, Mons U, Jenab M, Freisling H, Bueno-De-Mesquita HB, O'Doherty MG, Scott A, Kee F, Stricker BH, Hofman A, de Keyser, Ruiter, Söderberg S, Jousilahti P, Kuulasmaa K, Freedman ND, Wilsgaard T, de Groot LC, Kampman E, Håkansson N, Orsini N, Wolk A, Nilsson LM, Tjønneland A, Pająk, Malyutina S, Kúbinová, Tamosiunas A, Bobak M, Katsoulis M, Orfanos P, Boffetta P, Trichopoulou A, Brenner H. Quantification of the smoking-associated cancer risk with rate advancement periods: Meta-analysis of individual participant data from cohorts of the CHANCES consortium. BMC Medicine. 2016;14:62:1-15 | en_US |
dc.identifier.cristinID | FRIDAID 1422784 | |
dc.identifier.doi | 10.1186/s12916-016-0607-5 | |
dc.identifier.issn | 1741-7015 | |
dc.identifier.uri | https://hdl.handle.net/10037/10368 | |
dc.language.iso | eng | en_US |
dc.publisher | BioMed Central | en_US |
dc.relation.journal | BMC Medicine | |
dc.rights.accessRights | openAccess | en_US |
dc.subject | VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 | en_US |
dc.subject | VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 | en_US |
dc.title | Quantification of the smoking-associated cancer risk with rate advancement periods: Meta-analysis of individual participant data from cohorts of the CHANCES consortium | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |